GSK’s Malaria Vaccine Phase 3 Study Containing Agenus’ QS-21 Published in The Lancet

• Final study results show significant reduction in malaria cases

• EMA currently reviewing the regulatory application

LEXINGTON, Mass.-- Agenus Inc. (AGEN), an immunology company developing innovative treatments for cancers and other diseases, announced today that final results from a large-scale Phase 3 study of GlaxoSmithKline’s (GSK) malaria vaccine candidate, RTS,S, were published in The Lancet. The study demonstrated a statistically significant reduction against malaria in children who received RTS,S followed by a booster shot of the vaccine at 18 months. RTS,S incorporates QS-21 Stimulon^®, Agenus’ adjuvant designed to increase the immune response to antigens in vaccines.

Asterias Biotherapeutics Announces Phase 2 Clinical Data on Autologous Telomerase-based Dendritic Cell Cancer Vaccine AST-VAC1 Selected for Oral Presentation at the 2015 ASCO Annual Meeting

MENLO PARK, Calif., April 21, 2015  -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that the abstract describing long-term follow-up of patients with acute myelogenous leukemia (AML) from the Phase 2 clinical trial of the Company's autologous  telomerase-based dendritic cell cancer vaccine, AST-VAC1, has been selected for an oral presentation at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago, Illinois May 29 - June 2, 2015.

Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® Preclinical Data at the 2015 AACR Annual Meeting

CALGARY, April 20, 2015 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC.TO) (NASDAQ:ONCY) today announced that a series of poster presentations by the Company's research collaborators will be made at the 2015 AACR Annual Meeting being held from April 18^th to 22^nd, 2015 in Philadelphia, PA.

"Our preclinical program remains focused on identifying additional drug combinations, indications and genetic populations that we can consider for future clinical testing," said Dr. Brad Thompson, President and CEO of Oncolytics. "The findings presented at the AACR meeting are all supportive of additional work with these treatment combinations."

XBiotech Closes Initial Public Offering

AUSTIN, Texas, April 17, 2015 -- XBiotech Inc. (XBIT), a leading developer of next-generation therapeutic antibodies, announced today the closing of its initial public offering of 4,000,000 shares of its common stock at an initial public offering price of $19.00 per share for a total offering amount of $76,000,000, before the underwriting discounts and commissions and other company expenses.

WR Hambrecht + Co acted as the sole underwriter for the offering.